ASH 2023 | Final results of KarMMa-3: ide-cel in R/R MM

So this is actually a follow-up of what was our late-breaking abstract presentation last year, where we presented the initial results of the KarMMa-3 trial, in which patients with relapsed/refractory myeloma who had had four or more lines of treatment, received either ide-cel or a variety of standard of care treatments. And at that time, there was a significant benefit for patients receiving ide-cel, with a progression-free survival medium of around 18 months versus four months for standard of care, based on significant improvements in overall response rate, 70% versus 40%, and more importantly, a very high complete remission rate around 30% versus 4%. So, Dr Rodriguez today, will be presenting a follow-up in the final analysis of that study that was recently published in the New England Journal of Medicine. And the results are holding still; actually, the results for the ide-cel group have improved with, now, median progression-free survival being 18.8 months versus 4.4 months for the control group. And I think there will be also updated survival data that will be presented on Monday in the abstract presentation and I encourage everybody to go and see that. And this is all, again, based on significant improvements in both overall response rates and complete response rates.